Nathan Livingston

Nathan Livingston is currently an Analyst at Catalio Capital Management, where he specializes in identifying and evaluating early-stage biotechnology investment opportunities. In this capacity, his primary responsibilities involve conducting detailed technical and commercial due diligence on emerging therapeutics and diagnostics companies. His analytical work supports the firm's broader strategy of deploying capital into life sciences ventures that are developing new medical treatments and specialized clinical testing platforms. Operating within the healthcare investment sector, he assesses complex biological data, intellectual property portfolios, and regulatory pathways associated with pre-clinical and clinical-stage startup enterprises. By focusing on the intersection of scientific research and venture capital, he helps the fund navigate the technical landscape of early-stage medical investments. Livingston maintains a dedicated professional focus on sourcing and analyzing emerging therapeutics and diagnostic technologies to drive healthcare venture outcomes.